Mode
Text Size
Log in / Sign up
Phase 2 N=184 Randomized Single-blind Treatment

Behavioral Activation Intervention for Smoking Cessation in Smokers With Depressive Symptoms

Cigarette Smoking

Enrolled (actual)
184
Serious AEs
1.6%
Results posted
Sep 2020
Primary outcome: Primary: Number of Participants Smoking-Abstinent for 7 Days, 52 Weeks Post Quit Date — 26; 19 Participants

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
Standard Treatment (Behavioral); Behavioral Activation Treatment for Smoking (Behavioral); Transdermal Nicotine Patch (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
University of Maryland, College Park
Primary completion
May 2016

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants Smoking-Abstinent for 7 Days, 52 Weeks Post Quit Date
26; 19

Summary

Depression related vulnerabilities are highly comorbid with smoking behavior and dramatically reduce cessation rates among both community and clinical samples. Previous research has examined the efficacy of cognitive-behavioral treatment for individuals with a history of major depressive disorder (MDD) in standard cessation treatment. A broader health impact can be achieved by targeting individuals with current elevated depressive symptoms to address their association with cessation failure. Thus the objective of the present proposal is to conduct a Stage II randomized controlled trial (RCT) comparing the behavioral activation intervention to standard treatment among a similar community sample of 200 adult smokers with elevated depressive symptoms. Participants will be followed over 52 weeks post-quit date and the larger sample size will allow for more complex analysis of cessation outcomes.

Eligibility Criteria

Inclusion Criteria

  • Between 18 and 65 years of age
  • A regular smoker for at least one year
  • Currently smoking an average of at least 10 cigarettes per day
  • Want to quit smoking
  • Report current elevated depressive symptoms

Exclusion Criteria

  • Current Axis I disorder
  • Psychoactive substance dependence (excluding nicotine dependence) within the past 6 months
  • Current use of psychotropic medication or participation in any form of psychotherapy
  • A history of significant medical condition (e.g., cardiovascular , neurological, gastrointestinal), pregnancy and/or breast feeding, or other systemic illness
  • Current use of any pharmacotherapy for smoking cessation not provided by the researchers during the quit attempt
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01199380). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search